Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
BEST-MS: A Prospective Head-to-Head Comparative Study of Natalizumab and Fingolimod in Active Relapsing MSMult. Scler. 2020 Oct 30;[EPub Ahead of Print], M Cohen, L Mondot, F Bucciarelli, B Pignolet, DA Laplaud, S Wiertlewski, B Brochet, A Ruet, G Defer, N Derache, P Vermersch, H Zephir, M Debouverie, G Mathey, E Berger, C Cappé, P Labauge, C Carra, J De Seze, K Bigaut, D Brassat, C Lebrun-Frenay
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.